NCT01372644View on ClinicalTrials.gov

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

November 30, 2013

Conditions
Atypical Ductal Breast HyperplasiaLobular Carcinoma in Situ (LCIS)Atypical Lobular Hyperplasia (ALH) of Breast
Interventions
DRUG

SOM 230 / Pasireotide

Trial Locations (1)

10016

NYU School of Medicine, New York

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

NYU Langone Health

OTHER

NCT01372644 - Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial | Biotech Hunter | Biotech Hunter